Understanding women’s motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence
Abstract Background In biomedical prevention trials, correct and consistent use of the investigational product is crucial to determine efficacy. Product adherence in VOICE, a phase 2B randomized trial of a vaginal gel and oral tablets for HIV prevention, was low (~ 34%), yet self-reported adherence...
Main Authors: | Ariana W. K. Katz, Barbara S. Mensch, Kubashni Woeber, Petina Musara, Juliane Etima, Ariane van der Straten |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | BMC Women's Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12905-019-0713-6 |
Similar Items
-
The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study
by: Terry A. Jacot, et al.
Published: (2021-10-01) -
Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial
by: Terry A. Jacot, et al.
Published: (2021-09-01) -
Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies
by: Terry A. Jacot, et al.
Published: (2018-11-01) -
A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN‐035
by: José Bauermeister, et al.
Published: (2024-03-01) -
Preventing HIV transmission through blockade of CCR5: rationale, progress and perspectives
by: Elsa Martins, et al.
Published: (2018-01-01)